Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-371-375"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-371-375"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-371-5002
lpv:speaker	lp:Juozas Imbrasas2
lpv:spokenAs	substitute; REGI (2012-01-19--2014-06-30)3 member; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 member; EFD (2009-07-14--2014-06-30)3 member; TRAN (2012-01-19--2014-06-30)3 substitute; Delegation for relations with the Korean Peninsula (2012-02-15--2014-06-30)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3 unknown; Partija Tvarka ir teisingumas (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"I voted in favour of a directive of the European Parliament and of the Council amending Directive 2001/83/EC as regards pharmacovigilance. I welcome this amendment because it aims to further strengthen the pharmacovigilance system at EU level. The five additional amendments proposed serve to clarify wording, ensure that the workload of the Pharmacovigilance Risk Assessment Committee remains manageable, and to ensure that patients and health care professionals are fully involved in improving the pharmacovigilance system. Enhancing cooperation between Member States will ensure improved safety of medicines at EU level and will also avoid adverse effects such as in the Mediator case."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph